利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

49 条记录 (耗时 0.032 秒)

    2,2′,6,6′-tetrasubstituted aminophosphine ligand and its synthesis method
    3.
    发明授权
    2,2′,6,6′-tetrasubstituted aminophosphine ligand and its synthesis method 有权
    2,2'，6,6'-四取代氨基膦配体及其合成方法

    公开(公告)号：US08729303B2

    公开(公告)日：2014-05-20

    申请号：US12377000

    申请日：2007-08-10

    申请人： Wanbin Zhang ,  Fang Xie ,  Fang Fang

    发明人： Wanbin Zhang ,  Fang Xie ,  Fang Fang

    IPC分类号： C07F9/02

    CPC分类号： C07F9/46

    摘要： The present invention relates to a 2,2′,6,6′-tetrasubstituted aminophosphine ligand and its synthesis method. The structure of the ligand is shown as below. Its synthesis method comprises: Step (1) coupling 2,6-dinitrochlorobenzene as the starting material to obtain 2,2′,6,6′-tetranitrobiphenyl; Step (2): hydrogenating the 2,2′,6,6′-tetranitrobiphenyl with Pd/C to obtain 2,2′,6,6′-tetraminobiphenyl; Step (3): reacting the 2,2′,6,6′-tetraminobiphenyl with a phosphine halide to obtain the 2,2′,6,6′-tetrasubstituted aminophosphine ligand. The ligand of the present invention is an achiral compound, and its preparation method is simple. The ligand can be converted to a chiral bimetallic catalyst with single configuration eventually through introduction of external chirality. Moreover, the ligand can be used in various asymmetric reaction catalyzed by metals with high reactivity and stereoselectivity.

    摘要翻译： 本发明涉及2,2'，6,6'-四取代氨基膦配体及其合成方法。 配体的结构如下所示。 其合成方法包括：步骤（1）以2,6-二硝基氯苯为原料，得到2,2'，6,6'-四硝基联苯; 步骤（2）：用Pd / C氢化2,2'，6,6'-四硝基二苯并得到2,2'，6,6'-四氨基联苯; 步骤（3）：使2,2'，6,6'-四磺酰联苯与卤化膦反应，得到2,2'，6,6'-四取代氨基膦配体。 本发明的配体是非手性化合物，其制备方法简单。 最终可以通过引入外部手性将配体转化为具有单一配置的手性双金属催化剂。 此外，配体可用于由具有高反应性和立体选择性的金属催化的各种不对称反应中。

    Humanized antibodies
    5.
    发明授权
    Humanized antibodies 失效
    人源化抗体

    公开(公告)号：US07696324B2

    公开(公告)日：2010-04-13

    申请号：US11519322

    申请日：2006-09-11

    申请人： Fang Fang ,  Lori Kohlstaedt ,  John Reno

    发明人： Fang Fang ,  Lori Kohlstaedt ,  John Reno

    IPC分类号： C07K16/28 ,  C12P21/08

    CPC分类号： C07K16/2896 ,  A61K2039/505 ,  C07K16/2821 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2319/00 ,  Y02A50/412

    摘要： Humanized antibodies that bind ICAM-1 are provided. Antibodies include those selected from: SEQ ID NO:1 and 3 (HumA); SEQ ID NO:5 and 7 (HumB); SEQ ID NO:9 and 11 (HumC); SEQ ID NO:13 and 15 (HumD); SEQ ID NO:17 and 19 (HumE); SEQ ID NO:21 and 23 (HumF); SEQ ID NO:25 and 27 (HumG); SEQ ID NO:29 and 31 (HumH); and SEQ ID NO:33 and 35 (HumI). Subsequences of the humanized antibodies capable of binding an ICAM-1 epitope are also provided. Methods of inhibiting pathogen infection (e.g., HRV) of a cell employing humanized antibodies capable of binding an ICAM-1 epitope are further provided.

    摘要翻译： 提供了结合ICAM-1的人源化抗体。 抗体包括选自：SEQ ID NO：1和3（HumA）的那些; SEQ ID NO：5和7（HumB）; SEQ ID NO：9和11（HumC）; SEQ ID NO：13和15（HumD）; SEQ ID NO：17和19（HumE）; SEQ ID NO：21和23（HumF）; SEQ ID NO：25和27（HumG）; SEQ ID NO：29和31（HumH）; 和SEQ ID NO：33和35（HumI）。 还提供了能够结合ICAM-1表位的人源化抗体的子序列。 还提供了使用能够结合ICAM-1表位的人源化抗体抑制细胞病原体感染（例如HRV）的方法。

    Dog crate
    7.
    外观设计
    Dog crate 有权

    公开(公告)号：USD1021275S1

    公开(公告)日：2024-04-02

    申请号：US29919483

    申请日：2023-12-05

    申请人： Zhihui Zheng ,  Zihan Geng ,  Fang Fang

    设计人： Zhihui Zheng ,  Zihan Geng ,  Fang Fang

    摘要： FIG. 1 is a front, top, and left perspective view of a dog crate showing my new design;
    FIG. 2 is a front elevational view thereof;
    FIG. 3 is a rear elevational view thereof;
    FIG. 4 is a left side elevational view thereof;
    FIG. 5 is a right side elevational view thereof;
    FIG. 6 is a top plan view thereof;
    FIG. 7 is a bottom plan view thereof; and,
    FIG. 8 is a rear, bottom, and right perspective view thereof.
    The broken lines shown in the drawings represent portions of the dog crate that form no part of the claimed design.